MedTrace Logo

Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk

NCT03135067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2102

Last updated 2022-12-16

Study results available
· View outcomes & findings →

Summary

This cluster randomized trial will assess whether the provision of multiple oral-fluid based HIV self-test kits to HIV-negative women at high risk of acquiring HIV in western Kenya is an approach that promotes HIV testing among women's sexual partners, facilitates better sexual decision making, and reduces women's risk of acquiring HIV.

Conditions

  • Human Immunodeficiency Virus

Interventions

BEHAVIORAL

Provision of multiple self-tests

Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Impact Research & Development Organization

    collaborator OTHER

  • RTI International

    collaborator OTHER

  • University of North Carolina

    collaborator OTHER

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Harsha Thirumurthy, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-04
Primary Completion
2020-03-25
Completion
2020-03-25

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03135067 on ClinicalTrials.gov